Lung Cancer in Paul Wheatley-Price BSc, MBChB, MRCP (UK), MD
|
|
- Justina Daniels
- 5 years ago
- Views:
Transcription
1 Lung Cancer in 2015 Paul Wheatley-Price BSc, MBChB, MRCP (UK), MD Assistant Professor, Division of Medical Oncology, Department of Medicine, University of Ottawa 1
2 Disclosures Honorarium for advisory boards, invited speaking: Lilly, Astra Zeneca, Amgen, Pfizer, Boehringer Ingelheim, Merck 2
3 Before we get started... 3
4 Before we get started... I ll fight for the guy who doesn t have a voice 4
5 Who gets lung cancer? More common in low income groups More common in those with less education Overall a 5 year survival of 16-17% >20,000 deaths per year in Canada So who will be the voice? Mao et al, Int J Epidem 2001; 30 (4) ; Canadian Cancer Statistics 5
6 Stage 4 NSCLC in Ottawa N=528, seen as a new out-patient consult Only 55% received any systemic therapy Of those untreated, poor functional status in twothirds N=223, seen initially while hospitalized 24% received chemotherapy Ontario provincial data N=8113 Identified from linked provincial databases 70% saw a medical oncologist Only 24% received any systemic therapy (although that increased over time) Brule et al, ASCO 2015; Gotfrit et al, WCLC 2015 Sacher et al, ASCO
7 Barbera et al JCO
8 Lung Cancer Canada: Canada s only national charity solely dedicated to lung cancer. 8
9 9
10 Outline A journey to the current advanced NSCLC treatment algorithm, including... A brief overview of the last year with respects to: Me Canadian politics Lung Cancer 10
11 From this... 11
12 From this... 12
13 ... to this 13
14 ... to this 14
15 But do I know the Canadian politicians? 15
16 And do you?? 16
17 Milestones in lung cancer therapy First evidence showing longer survival with palliative chemotherapy First evidence to show benefit from second line therapy First evidence for the role of adjuvant chemotherapy 3 rd line therapy The molecular era Immunooncology 17
18 Case 1 62 year old female Seen in February month of painful back mass 50 pack years, quit in 2011 PS-1 18
19 Case 1 Pathology Poorly differentiated adenocarcinoma Received palliative RT to paraspinal mass, then developed left sided weakness 19
20 Case 1 Neurosurgery for debulking Cyberknife RT to the tumour bed Now PS-2 Options? 20
21 Case 1 Neurosurgery for debulking Cyberknife RT to the tumour bed Now PS-2 Options? Palliative chemotherapy Best supportive care 21
22 Who was Canadian PM in 1995? 1. Brian Mulroney 2. Kim Campbell 3. Jean Chrétien 22
23 Who was Canadian PM in 1995? Brian Mulroney Kim Campbell Jean Chrétien Bonus question: Who was the British PM in 1995? 23
24 1995: Chemotherapy prolongs survival First analysis to show longer survival with platinum chemotherapy 1-year survival of 25% versus 15% Median survival with chemotherapy improved by approximately 6 weeks Non-small Cell Lung Cancer Collaborative Group, BMJ 1995;311:
25 A choice of platinum doublets Median survival with chemotherapy 8.0 months Schiller et al, NEJM 2002; 346(2):
26 Histology matters 26
27 Histology matters Pemetrexed is superior in non-squamous NSCLC Scagliotti et al. J Clin Onc; 2008;26(21):
28 Case 1 initial treatment Tested for EGFR and ALK (more later) both negative Commenced platinum doublet chemotherapy cisplatin / pemetrexed Hearing loss / tinnitus developed, so cisplatin switched to carboplatin Pre chemo Post-chemo 28
29 How much / how long? Trial Treatment Number Overall survival P-value Carbo / Taxol (Socinski et al) MVP (Smith et al) Carbo / Vinorelbine (von Plessen et al) Platinum doublet (Park et al) 4 cycles mo 0.63 Until progression mo 3 cycles mo cycles mo 3 cycles wk cycles wk 4 cycles mo cycles mo 29
30 Can the benefits of initial treatment be maintained? 30
31 Or are they destined to end badly? 31
32 Who was Liberal party leader in 2009? 1. Stéphane Dion 2. Michael Ignatieff 3. Bob Rae 32
33 Who was Liberal party leader in 2009? 1. Stéphane Dion 2. Michael Ignatieff 3. Bob Rae 33
34 Maintenance therapy Switch maintenance Induction platinum doublet, then change to new single agent as maintenance Continuation maintenance Induction platinum doublet, then continue with the nonplatinum agent The evidence Phase III studies of maintenance pemetrexed treatment after platinum doublet 1 st line therapy 34
35 Maintenance pemetrexed Switch maintenance Median overall survival Pemetrexed: 13.4 months Placebo: 10.6 months HR 0.79 ( ), p=0.01 Ciuleanu T, et al. Lancet 2009;374: Continuation maintenance Median overall survival Pemetrexed: 13.9 months Placebo: 11.0 months HR 0.78 ( ), p=0.02 PARAMOUNT Trial. Paz Ares et al. JCO 2013;31:
36 Case 1 an update Seen in clinic on 28 th September 2015 Now receiving maintenance pemetrexed (6 cycles so far) Ongoing shrinkage of metastatic disease Ongoing hearing loss Heading to Las Vegas this weekend 36
37 Who was USA VP in 2000? 1. Al Gore 2. Dick Cheney 3. Dan Quayle 37
38 Who was USA VP in 2000? 1. Al Gore 2. Dick Cheney 3. Dan Quayle 38
39 Prolonged survival on progression 2000: efficacy of further CT after platinum failure Docetaxel versus best supportive care Median survival 7.0 months versus 4.6 months Shepherd et al. J Clin Oncol; 18:
40 2004: Pemetrexed in 2 nd -line Median survival with chemotherapy: months Hanna et al. J Clin Oncol; 22:
41 The second line space is becoming crowded more later 41
42 Who was Canadian PM in 2005? 1. Jean Chrétien 2. Paul Martin 3. Stephen Harper 42
43 Who was Canadian PM in 2005? 1. Jean Chrétien 2. Paul Martin 3. Stephen Harper 43
44 Erlotinib as 2 nd /3 rd line treatment BR.21 Study Erlotinib or placebo after failure of chemotherapy in advanced NSCLC 488 patients received erlotinib 243 patients received placebo Shepherd et al. NEJM 353; ,
45 BR.21 - Results Median overall survival 6.7 v 4.7 months (p<0.001) Response best seen in never-smokers, adenocarcinoma and EGFR expressors Shepherd et al. NEJM 353; ,
46 Treatment algorithm Patients with advanced NSCLC and good PS 1 st line Platinum doublet CT Maintenance Maintenance pemetrexed 2 nd line Pemetrexed or Docetaxel 3 rd line Erlotinib 46
47 The targeted era is here 47
48 Case 2: 40 year old male Previously healthy Never smoker Presented with 1 year of visual changes RUL adenocarcinoma with a right sided retinal metastasis EGFR mutation detected (exon 19 deletion) 48
49 EGFR mutation population There are numerous randomized phase 3 studies comparing EGFR TKI to chemotherapy in EGFR m+ NSCLC, all showing significant benefits to the targeted therapy Erlotinib (Erlotinib ) Gefitinib (Iressa ) Afatinib (Giotrif ) 49
50 1 st line gefitinib vs chemotherapy Han et al. NEJ002. NEJM 2010 (362):
51 1 st line erlotinib vs chemotherapy Rossel et al. EURTAC. Lancet Oncology 2012 (13):
52 1st line afatinib vs chemotherapy Sequist et al. LUX-LUNG 3. JCO 31(27): ,
53 Case 2: Progress on treatment Commenced gefitinib 250mg od Jan 2012 Grade 1 rash and diarrhea Vision improved within a few weeks Dec 2011 March
54 What is ALK? Approximately 3-4% NSCLC have a genetic rearrangement called EML4-ALK Chromosome 2 fusion gene created by an inversion that juxtaposes Echinoderm microtubule-associated protein-like 4 (EML4) [2p21) Anaplastic lymphoma kinase (ALK) [2p23] This leads to a novel fusion oncogene EML4- ALK, a 200-kDa transmembrane tyrosine kinase 54
55 Shaw and Solomon. Clin Canc Res 2011;17:
56 The rapid history of ALK EML4-ALK was first identified in a 62 year old Japanese lung adenocarcinoma patient in 2007 Crizotinib had actually entered first-in-man studies in 2006 First study patient for ALK+ NSCLC was August 27 th 2008 FDA granted accelerated approval to crizotinib on August 26 th 2011 Health Canada approval April 2012 CCO funding October
57 Efficacy Response rate (CR/PR) 61% Disease control rate (CR/PR/SD) 83% PFS 9.7 m PFS (1 st line) 18.3 m Camidge. Lancet Oncology 2012; 13 (10):
58 Crizotinib oral agent targeting ALK Camidge et al. Lancet Oncology (epub Sept 2012) 58
59 Crizotinib vs Chemotherapy Crizotinib versus platinum / pemetrexed chemotherapy as 1 st line treatment for stage 4 ALK-positive lung cancer Solomon et al. NEJM 2014; 371(23):
60 Crizotinib vs Chemotherapy Crizotinib versus docetaxel or pemetrexed chemotherapy as 2nd line treatment for stage 4 ALK-positive lung cancer Shaw et al. NEJM 2014; 368(25):
61 Standard of care Early 2014 Patients with advanced NSCLC and good PS EGFR mutation positive EGFR / ALK ve NSCLC ALK translocation positive Gefitinib / Erlotinib / Afatinib Pemetrexed Platinum doublet CT Pemetrexed (m) Non- Squamous Squamous Docetaxel Crizotinib Erlotinib 61
62 The news from 2015 that affects us 1. For those with actionable mutations, there are now more lines of non-cytotoxic therapy 2. We are in the era of immuno-oncology 62
63 Case 2 an update The response to gefitinib lasted 1 year 4 cycles cis / pemetrexed - no response Brief response to afatinib: Mar-Sep 2014 Sept 2014 functional decline Liver, brain and lung metastases Not keen on docetaxel (low response rate) Biopsy repeated T790M mutation 63
64 Targeting T790M T790M is a mutation that commonly emerges The most common resistance mechanism to first line EGFR TKI therapy A number of 3 rd generation TKIs target common mutations and T790M Osimertinib (AZD9291) Rociletinib (CO-1686) 64
65 Case 2: Enrolled on trial of 3 rd gen EGFR TKI Baseline scans September
66 Case 2: Spectacular response Baseline Repeat scans after 4 weeks 66
67 Case 2: Spectacular response Baseline Repeat scans after 4 weeks 67
68 AZD 9291 Janne et al. NEJM 2015; 372(18):
69 Also 2 nd generation ALK inhibitors Multiple 2 nd line ALK inhibitors: Ceritinib (Novartis) Alectinib (Roche) Brigatinib (Ariad) Ceritinib (Zykadia) is commercially available, Health Canada approved, but not publicly reimbursed 69
70 Crizotinib as a ROS1 inhibitor ROS1 oncogene Related to ALK 1% NSCLC Never smokers Adenocarcinoma Phase 1 study of crizotinib in ALK, then included a ROS1 expansion cohort N=50 Shaw et al. NEJM Sept
71 Immunotherapy Immune checkpoint inhibitors Cancer cells express ligands that supress T-cell response Inhibition of these inhibitory effects allows T-cell response 2013 Drug of the year: PD-1 and PD-L1 monoclonal antibodies. Breakthrough of the Year
72 Different mechanisms Antibodies against PD-1 prevent the binding of inhibitory ligands PD-L1 or PD-L2 Antibodies against PD- L1 prevent the ligand from binding to PD-1 or B7-1 Topalian et al, Current Opinion in Immunology 2012; 24:
73 Immune checkpoint inhibitors. Who are the main players? Almost all NSCLC data is from conference abstracts / presentations, and not from published trials 73
74 Leading PD-1 and PD-L1 antibodies Anti PD-1 Nivolumab Bristol-Myers Squib IgG4 Pembrolizumab Merck IgG4 (humanized) Anti PD-L1 Atezolizumab Genentech / Roche IgG1 Durvalumab MedImmune / AstraZeneca Modified IgG1 74
75 Leading PD-1 and PD-L1 antibodies Drug Number Response rate Nivolumab % Pembrolizumab % Atezolizumab 52 23% Durvalumab % Brahmer et al, ASCO 2014; Garon et al, ESMO 2014; Horn et al, WCLC 2013; Brahmer et al, ASCO
76 A year ago we were asking? Are these an exciting news story that will not turn into anything? 76
77 A year ago we were asking? Are these an exciting news story that will not turn into anything? 77
78 A year ago we were asking? Are these an exciting news story that will not turn into anything? Or will it be a true winner? 78
79 These drugs are here to stay 2 nd line treatment advanced squamous cell lung cancer Brahmer et al, NEJM 2015; 373 (2) :
80 These drugs are here to stay 2 nd line treatment advanced non-squamous cell lung cancer Paz Ares, ASCO Slide courtesy of BMS 80
81 Are these drugs well tolerated? In general yes Grade 3-4 toxicities in only 7% cases (compared to 55% in docetaxel) Immune-related side effects uncommon Hypothyroidism Pneumonitis Colitis Administered iv every 2-3 weeks (depends on which drug) 81
82 2015 State of Play Patients with advanced NSCLC and good PS Line EGFR positive ALK positive ROS1 positive Wildtype NSCLC 1 st Gefitinib / Erlotinib Afatinib Crizotinib Crizotinib Platinum doublet CT Main Maintenance pemetrexed 2 nd 3 rd gen TKI 2 nd gen ALK Pemetrexed or Docetaxel Nivolumab 3rd Erlotinib 82
83 For those who In summary Get to see a medical oncologist Are fit for treatment There are now multiple treatment options, and often well tolerated An exciting time in thoracic oncology However we must advocate for the whole lung cancer population 83
84 Thank you for your attention 84
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer Page 1 of 41 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proteomic Testing for Systemic
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationSquamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression
Squamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression David R. Spigel, M.D. Program Director, Lung Cancer Research Sarah Cannon Research Institute Nashville, TN Case of NR: Initial
More informationAccepted Manuscript. C. Gridelli, B. Besse, J.R. Brahmer, L. Crino, E. Felip, F. de Marinis. S (16) /j.cllc
Accepted Manuscript The evolving role of nivolumab in non-small-cell lung cancer for second-line treatment: a new cornerstone for our treatment algorithms. Results from an International Experts Panel Meeting
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationMedical Policy. MP Proteomic Testing for Targeted Systemic in Non-Small-Cell Lung Cancer
Medical Policy MP 2.04.125 Proteomic Testing for Targeted Systemic in Non-Small-Cell Lung Cancer BCBSA Ref. Policy: 2.04.125 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer Page 1 of 43 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proteomic Testing for Systemic
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationClinical Policy Title: Advanced non-small cell lung cancer with TKI and PD-1 drugs
Clinical Policy Title: Advanced non-small cell lung cancer with TKI and PD-1 drugs Clinical Policy Number: 05.02.11 Effective Date: March 1, 2017 Initial Review Date: February 15, 2017 Most Recent Review
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationProteomic Testing for Systemic Therapy in Non-Small Cell Lung Cancer
Proteomic Testing for Systemic Therapy in Non-Small Cell Lung Cancer Policy Number: 2.04.125 Last Review: 6/2018 Origination: 12/2014 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationPersonalized Medicine in Oncology and the Implication for Clinical Development
THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Non-Small Cell Lung Cancer
pan-canadian Oncology Drug Review Final Clinical Guidance Report Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Non-Small Cell Lung Cancer November 2, 2017 DISCLAIMER Not a Substitute for Professional
More informationHacia una mayor individualización clínica en el CPNM. J.M. Sánchez Torres H.U. Princesa, Madrid
Hacia una mayor individualización clínica en el CPNM J.M. Sánchez Torres H.U. Princesa, Madrid Lung cancer histologic subtypes NSCLC (80-85%) SCLC (15-20%) Squamous carcinoma (25 30%) Non-squamous carcinoma
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationLung Cancer: Personalized Approaches to Non-Small Cell and Small Cell Lung Cancer
Lung Cancer: Personalized Approaches to Non-Small Cell and Small Cell Lung Cancer Speaker: Bruce E. Johnson, MD Chief Clinical Research Officer, Dana-Farber Cancer Institute Professor of Medicine, Harvard
More information